Research and development of new drugs for nonalcoholic steatohepatitis (NASH), financing nearly 200 million RMB in round a for dabio

At the beginning of the new year, focusing on the development of new drugs for critical metabolic diseases, we first completed a round of financing of nearly 200 million yuan for dabio, led by Junlian capital, followed by Shiyu capital, an old shareholder, and Kain technology "We are committed to developing safe and effective new protein and peptide drugs for the treatment of critical metabolic diseases, especially non-alcoholic steatohepatitis (NASH) caused by diabetes or obesity In 2019, xianweida will have 2 class I new drugs with international intellectual property rights submitted to ind " Dr pan Hai, chairman and general manager of the company, said, "this financing will provide an effective financial guarantee for the company's long-term development strategy Here, I am very grateful to the new and old shareholders for their high trust and strong support to pioneer bio." In China alone, there are at least 20 million people suffering from Nash, 30% of whom are likely to develop cirrhosis or liver cancer, and there are huge unmet medical needs Moreover, the obesity and type II diabetes that can induce NASH are spreading all over the world Liver experts see that patients with NASH are getting younger and younger, which further intensifies the potential medical needs of NASH The Nash new drug project of dabio may bring breakthroughs to benefit Chinese and global NASH patients Dr pan Hai said, "there is a huge market capacity in the field of Nash treatment Although many pharmaceutical enterprises are currently engaged in the research and development of Nash related new drugs, the first step is to develop new biological drugs for NASH treatment through combination therapy from three different perspectives of metabolism, inflammation and fibrosis, with biological drugs as the leading role." Excellent team with experience of top biopharmaceutical companies in Europe and America to build high-quality R & D pipeline First, we have a highly international R & D and management team Many of our executives are from Amgen Inc., Novo Nordisk, Pfizer and other top European and American biopharmaceutical companies We have rich experience in the development and industrialization of new biological drugs in the world Our R & D team is fully equipped with the technical strength to independently develop new biological drugs At the beginning of the company's establishment, adhering to the concept of "science first, practical work first, and gentlemen also reach", the company first positioned its goal as an international company of innovative drug development, looked at the world and served China, and constantly explored new treatment methods for metabolic critical diseases, the breakthrough was fatty hepatitis, liver fibrosis and cirrhosis Dr pan Hai, chairman and general manager of the company, has been engaged in new drug research in the field of liver disease for a long time He has rich experience in new drug research and development in the whole chain of research and development of new drugs such as recombinant protein drugs, peptide drugs and small molecule drugs He is an expert in the field of macromolecular biological products industrialization and liver disease, especially in the field of liver disease treatment He has made outstanding achievements in new drug development, and is a large number of returnees Among the experts, a few leading talents have achieved the listing and production reporting of multiple new drugs In more than one year since its establishment, the company has laid out high-quality, diversified and independent intellectual property R & D pipelines, effectively promoted pre clinical research of various projects, and actively explored the best combination drug treatment scheme for NASH by adopting the research strategy of combination therapy Professional investment institutions Junlian capital and Shiyu capital highly trust and fully promote the research and development of new drugs for Dachuang As the leading investor in this round of financing, Wang Junfeng, general manager of Junlian capital, said: "China's biopharmaceutical industry is in a golden period of rapid development Nash (non-alcoholic fatty hepatitis) is a huge unmet clinical demand, and it is an opportunity that cannot be missed behind Before deciding to invest, Junlian capital made a comprehensive and in-depth due diligence on new drug varieties, development capacity, patent layout, etc of Weida bio We believe that the development potential of pioneer bio is huge, and we are also confident in the team and new drugs of pioneer bio! " From pre-A round leading investment to a round of additional investment, Shiyu capital went all the way together In this regard, Yang Hongbing, founding partner of Shiyu capital, said: "first for reaching biology is a key incubation metabolic disease treatment company of Shiyu capital As an investment in innovative drugs, the founding team is crucial Our founding team has strong R & D ability and clinical research experience of new drugs, good cooperation spirit and extraordinary implementation ability, and complete experience of new drugs from pre clinical to market We are very optimistic about the development prospect of pioneer "